OncoMed Pharmaceuticals, Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2018. For the quarter, the company reported total revenue of $6,870,000 compared to $6,195,000 a year ago.  Net loss was $3,976,000 or $0.10 per basic and diluted share compared to $15,225,000 or $0.40 per basic and diluted share a year ago. Loss from operations was $4,888,000 against $15,435,000 for the same period a year ago. Loss before income taxes was $4,364,000 against $15,221,000 for the same period a year ago. For the six months, the company reported total revenue of $14,719,000 compared to $12,408,000 a year ago.  Net loss was $9,550,000 or $0.25 per basic and diluted share compared to $37,833,000 or $1.01 per basic and diluted share a year ago. Loss from operations was $10,820,000 against $38,193,000 for the same period a year ago. Loss before income taxes was $9,933,000 against $37,825,000 for the same period a year ago.